ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money in exchange-traded funds (ETFs) that track the performance of ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with ...

Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...